• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Evommune Inc.

    4/21/26 4:06:29 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVMN alert in real time by email
    DEFA14A
    false0002044725DEFA14A00020447252025-01-012025-12-31

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.   )

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under § 240.14a-12

     

    EVOMMUNE, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

    img41218707_0.jpg

    EVOMMUNE, INC. 1891 PAGE MILL ROADPALO ALTO, CA 94304 SCAN TO VIEW MATERIALS & VOTE VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time on June 1, 2026. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/EVMN2026 You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time on June 1, 2026. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 by 11:59 P.M. Eastern Time on June 1, 2026. V89967-P50550 EVOMMUNE, INC.ForWithholdForAll To withhold authority to vote for any individualAll AllExceptnominee(s), mark "For All Except" and write theThe Board of Directors recommends you votenumber(s) of the nominee(s) on the line below. "FOR" the following: !!! 1.To elect two nominees for Class I directors, each to hold office until the 2029 Annual Meeting of Stockholders. Nominees: 01)Luis Peña 02)Eugene A. Bauer ForAgainstAbstain The Board of Directors recommends you vote "FOR" the following proposal: 2.To ratify the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s independent registered!!! public accounting firm for the fiscal year ending December 31, 2026. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponements thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint ownersshould each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.
     

     


     

    img41218707_1.jpg

    Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice, Proxy Statement and Annual Report are available at www.proxyvote.com. V89968-P50550 EVOMMUNE, INC. Annual Meeting of Stockholders June 2, 2026 11:30 A.M. Eastern Time This proxy is solicited on behalf of the Board of Directors The stockholder(s) hereby appoint(s) Luis Peña, Gregory Moss and Kyle Carver, or either of them, as proxies, each with the power to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot (with discretionary authority under Proposal 1 to vote for a substitute nominee if any nominee is unable to serve or for good cause will not serve), all of the shares of Common Stock of EVOMMUNE, INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 11:30 A.M. Eastern Time, on June 2, 2026, virtually at www.virtualshareholdermeeting.com/EVMN2026, and any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations. It will be voted in the discretion of the proxies upon such other matters as may properly come before the Annual Meeting Continued and to be signed on reverse side

     


    Get the next $EVMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVMN

    DatePrice TargetRatingAnalyst
    4/7/2026$50.00Outperform
    Oppenheimer
    1/22/2026$42.00Outperform
    Oppenheimer
    1/8/2026$40.00Strong Buy
    Raymond James
    1/6/2026$35.00Buy
    H.C. Wainwright
    12/1/2025$42.00Outperform
    Leerink Partners
    12/1/2025$36.00Overweight
    Morgan Stanley
    12/1/2025Outperform
    William Blair
    12/1/2025$40.00Outperform
    Evercore ISI
    More analyst ratings

    $EVMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Patel Jeegar Pravinkumar

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:24:42 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Drew Janice Suzann

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:24:26 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bauer Eugene

    4 - Evommune, Inc. (0002044725) (Issuer)

    4/17/26 5:23:59 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Evommune with a new price target

    Oppenheimer resumed coverage of Evommune with a rating of Outperform and set a new price target of $50.00

    4/7/26 8:50:59 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Evommune with a new price target

    Oppenheimer initiated coverage of Evommune with a rating of Outperform and set a new price target of $42.00

    1/22/26 8:46:17 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Evommune with a new price target

    Raymond James initiated coverage of Evommune with a rating of Strong Buy and set a new price target of $40.00

    1/8/26 8:54:08 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

    Company to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET). The event will include presentations from members of Evommune's management team and the following two leading experts in migraine: Stewart

    4/6/26 9:00:00 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    – Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively – Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028 Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

    3/5/26 4:01:00 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evommune Announces $125 Million Private Placement

    Evommune, Inc. ("Evommune" or the "Company") (NYSE:EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of each share of common stock is $27.88. Evommune anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any transaction-related expenses. The private placement is expected to close on or about Feb

    2/12/26 8:30:00 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hopfner Robert Lorne bought $17,350 worth of shares (1,000 units at $17.35) (SEC Form 4)

    4 - Evommune, Inc. (0002044725) (Issuer)

    12/22/25 7:07:35 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    SEC Filings

    View All

    SEC Form DEFA14A filed by Evommune Inc.

    DEFA14A - Evommune, Inc. (0002044725) (Filer)

    4/21/26 4:06:29 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Evommune Inc.

    DEF 14A - Evommune, Inc. (0002044725) (Filer)

    4/21/26 4:05:36 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Evommune Inc.

    S-1 - Evommune, Inc. (0002044725) (Filer)

    4/17/26 4:05:52 PM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVMN
    Financials

    Live finance-specific insights

    View All

    Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

    - Trial met primary efficacy endpoint at week 12 - EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo - 33% placebo-adjusted improvement in EASI at week 12 - 23% of EVO301 patients achieved IGA 0/1 at week 12 - Company to hold conference call and webcast at 8:30 a.m. ET today Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of

    2/10/26 7:30:00 AM ET
    $EVMN
    Biotechnology: Pharmaceutical Preparations
    Health Care